Constitutive Aberrant Endogenous Interleukin-1 Facilitates Inflammation and Growth in Human Melanoma
- 15 November 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 9 (11), 1537-1550
- https://doi.org/10.1158/1541-7786.mcr-11-0279
Abstract
Interleukin (IL)-1–mediated inflammation is proposed to contribute to the development and progression of some cancers. IL-1 family member proteins are known to be expressed constitutively in many melanoma tumor cells, and we hypothesize that these support molecular pathways of inflammation and facilitate tumor growth. To investigate the expression of IL-1α and IL-1β in melanoma patients, and their association with disease progression, immunohistochemical staining was carried out on tissues from 170 patients including benign nevi, primary melanomas, and metastatic melanomas. IL-1β levels were low (or zero) in benign nevi and higher in primary and metastatic melanomas (P < 0.0001). IL-1α was expressed in about 73% of nevi and 55% of metastatic melanomas, with levels significantly higher in primary tumors (P < 0.0001); most (98%) primary melanoma samples were positive for IL-1α. In vitro studies with seven human melanoma cell lines showed that five cell lines expressed IL-1α and IL-1β proteins and mRNA. We identified for the first time several important downstream signaling pathways affected by endogenous IL-1, including reactive oxygen and nitrogen species, COX-2, and phosphorylated NF-κB inhibitor (IκB) and stress-activated protein kinase/c-jun-NH2-kinase; all of which were decreased by siRNA to IL-1s. Downregulation of IL-1α, IL-1β, or MyD88 substantially increased p21 and p53 levels. Treatment with IL-1 receptor type I neutralizing antibody or IL-1 pathway–specific siRNAs led to growth arrest in IL-1–positive melanoma cells. Furthermore, blocking the IL-1 pathway increased autophagy in IL-1–positive melanoma cells. These results indicate that the endogenous IL-1 system is functional in most human melanoma and interrupting its signaling inhibits the growth of IL-1–positive melanoma cells. Mol Cancer Res; 9(11); 1537–50. ©2011 AACR.Keywords
Other Versions
This publication has 38 references indexed in Scilit:
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends in Immunology, 2010
- Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray studyJournal of Cutaneous Pathology, 2010
- IL-1-induced ERK1/2 activation up-regulates p21Waf1/Cip1 protein by inhibition of degradation via ubiquitin-independent pathway in human melanoma cells A375Biochemical and Biophysical Research Communications, 2010
- Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1βJournal of Biological Chemistry, 2010
- Involvement of JNK in the regulation of autophagic cell deathOncogene, 2010
- Secreted Interleukin-1α Induces a Metastatic Phenotype in Pancreatic Cancer by Sustaining a Constitutive Activation of Nuclear Factor-κBMolecular Cancer Research, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectivesImmunological Reviews, 2008
- Small molecule regulators of autophagy identified by an image-based high-throughput screenProceedings of the National Academy of Sciences, 2007
- Altered macrophage differentiation and immune dysfunction in tumor developmentJCI Insight, 2007